Display options
Cite
Sellitto A, Pecoraro G, Giurato G, et al. Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143485.
Sellitto, A., Pecoraro, G., Giurato, G., Nassa, G., Rizzo, F., Saggese, P., Martinez, C. A., Scafoglio, C., & Tarallo, R. (2021). Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer. Cancers, 13(14), . https://doi.org/10.3390/cancers13143485
Sellitto, Assunta, et al. "Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143485
Sellitto A, Pecoraro G, Giurato G, Nassa G, Rizzo F, Saggese P, Martinez CA, Scafoglio C, Tarallo R. Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer. Cancers (Basel). 2021 Jul 12;13(14). doi: 10.3390/cancers13143485. PMID: 34298698; PMCID: PMC8308086.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jul 12;13(14). doi: 10.3390/cancers13143485.

Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer.

Cancers

Assunta Sellitto, Giovanni Pecoraro, Giorgio Giurato, Giovanni Nassa, Francesca Rizzo, Pasquale Saggese, Cesar A Martinez, Claudio Scafoglio, Roberta Tarallo

Affiliations

  1. Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy.
  2. Genome Research Center for Health-CRGS, University of Salerno Campus of Medicine, 84081 Baronissi, Italy.
  3. Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.

PMID: 34298698 PMCID: PMC8308086 DOI: 10.3390/cancers13143485

Abstract

Metabolic reprogramming is a well described hallmark of cancer. Oncogenic stimuli and the microenvironment shape the metabolic phenotype of cancer cells, causing pathological modifications of carbohydrate, amino acid and lipid metabolism that support the uncontrolled growth and proliferation of cancer cells. Conversely, metabolic alterations in cancer can drive changes in genetic programs affecting cell proliferation and differentiation. In recent years, the role of non-coding RNAs in metabolic reprogramming in cancer has been extensively studied. Here, we review this topic, with a focus on glucose, glutamine, and lipid metabolism and point to some evidence that metabolic alterations occurring in cancer can drive changes in non-coding RNA expression, thus adding an additional level of complexity in the relationship between metabolism and genetic programs in cancer cells.

Keywords: Warburg effect; cancer metabolism; glutaminolysis; glycolysis; lipid metabolism; long non-coding RNAs; metabolic reprogramming

References

  1. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18697-702 - PubMed
  2. Oncotarget. 2015 Feb 10;6(4):2451-65 - PubMed
  3. Nat Rev Cancer. 2018 Jan;18(1):5-18 - PubMed
  4. Int J Oncol. 2012 Sep;41(3):985-94 - PubMed
  5. ACS Appl Mater Interfaces. 2019 Jan 9;11(1):37-42 - PubMed
  6. Mol Cancer. 2019 Mar 2;18(1):33 - PubMed
  7. Clin Cancer Res. 2018 Oct 1;24(19):4808-4819 - PubMed
  8. Neuro Oncol. 2010 Nov;12(11):1102-12 - PubMed
  9. Mol Ther Nucleic Acids. 2020 Mar 6;19:751-758 - PubMed
  10. J Mol Biol. 2013 Oct 9;425(19):3698-706 - PubMed
  11. J Biomol Screen. 2015 Oct;20(9):1132-41 - PubMed
  12. Oncol Rep. 2017 Jan;37(1):3-9 - PubMed
  13. Gastroenterology. 2019 Feb;156(3):676-691.e11 - PubMed
  14. Nat Commun. 2014 Oct 10;5:5212 - PubMed
  15. Nat Commun. 2019 Aug 2;10(1):3499 - PubMed
  16. Drug Resist Updat. 2020 May;50:100683 - PubMed
  17. J Transl Med. 2020 Apr 3;18(1):152 - PubMed
  18. Cold Spring Harb Perspect Biol. 2014 Feb 01;6(2): - PubMed
  19. Am J Respir Cell Mol Biol. 1995 Oct;13(4):466-76 - PubMed
  20. RNA. 2008 Feb;14(2):336-46 - PubMed
  21. PLoS Genet. 2015 Dec 28;11(12):e1005726 - PubMed
  22. Oncotarget. 2015 Aug 14;6(23):19456-68 - PubMed
  23. Jpn J Clin Oncol. 2015 Nov;45(11):1055-63 - PubMed
  24. Cancers (Basel). 2019 Jun 12;11(6): - PubMed
  25. J Hematol Oncol. 2018 Aug 22;11(1):106 - PubMed
  26. Cell Death Dis. 2020 Aug 11;11(8):676 - PubMed
  27. Nat Commun. 2021 Feb 26;12(1):1341 - PubMed
  28. Oncogene. 2010 Jul 29;29(30):4362-8 - PubMed
  29. Mol Cancer. 2019 Feb 4;18(1):20 - PubMed
  30. Nat Rev Genet. 2011 Nov 18;12(12):861-74 - PubMed
  31. Int J Oncol. 2012 Jan;40(1):185-93 - PubMed
  32. Oncogene. 2013 Feb 7;32(6):797-802 - PubMed
  33. Cancer Res. 2018 Aug 15;78(16):4524-4532 - PubMed
  34. Oncogene. 2018 Mar;37(12):1624-1636 - PubMed
  35. Hepatology. 2018 Jan;67(1):188-203 - PubMed
  36. Nat Cell Biol. 2016 Feb;18(2):213-24 - PubMed
  37. Biochim Biophys Acta. 2014 Feb;1843(2):372-86 - PubMed
  38. FASEB J. 2021 Apr;35(4):e21438 - PubMed
  39. Cancer Lett. 2020 Jan 28;469:111-123 - PubMed
  40. Mol Cell. 2014 Jan 9;53(1):88-100 - PubMed
  41. Oncol Rep. 2012 Oct;28(4):1346-52 - PubMed
  42. J Gene Med. 2013 Feb;15(2):65-77 - PubMed
  43. Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):698-709 - PubMed
  44. J Clin Endocrinol Metab. 1996 Jul;81(7):2653-62 - PubMed
  45. Mol Cancer. 2017 Sep 25;16(1):154 - PubMed
  46. Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7653-7659 - PubMed
  47. Curr Genomics. 2015 Oct;16(5):319-26 - PubMed
  48. Front Physiol. 2016 Aug 08;7:342 - PubMed
  49. Int J Biol Sci. 2021 Jan 1;17(1):107-118 - PubMed
  50. Dev Dyn. 2019 Nov;248(11):1059-1069 - PubMed
  51. Front Oncol. 2020 May 29;10:810 - PubMed
  52. Cancer Lett. 2018 Apr 10;419:167-174 - PubMed
  53. Nat Med. 2011 Nov 20;17(12):1627-35 - PubMed
  54. Pathol Int. 2011 Jan;61(1):19-27 - PubMed
  55. Nat Cell Biol. 2015 Feb;17(2):183-94 - PubMed
  56. EMBO J. 2017 Dec 1;36(23):3483-3500 - PubMed
  57. Oncogene. 2020 Jun;39(25):4854-4868 - PubMed
  58. Nat Commun. 2017 Oct 4;8(1):783 - PubMed
  59. Eur J Cancer Prev. 2016 Nov;25(6):481-9 - PubMed
  60. Cell Metab. 2015 Oct 6;22(4):577-89 - PubMed
  61. Oncogene. 2009 Sep 24;28(38):3371-9 - PubMed
  62. Cell Death Differ. 2019 May;26(5):843-859 - PubMed
  63. Cancer Lett. 2017 Aug 1;400:89-98 - PubMed
  64. Nat Rev Cancer. 2006 Nov;6(11):857-66 - PubMed
  65. Leukemia. 2018 Sep;32(9):1948-1957 - PubMed
  66. Nat Biotechnol. 2013 Jun;31(6):522-9 - PubMed
  67. Cancer Res. 2019 Apr 1;79(7):1398-1412 - PubMed
  68. Front Cell Dev Biol. 2019 Jan 29;7:4 - PubMed
  69. Surgery. 2004 Sep;136(3):548-56 - PubMed
  70. Mol Cell Biol. 2012 May;32(10):1893-907 - PubMed

Publication Types

Grant support